Title : Alisertib added to rituximab and vincristine is synthetic lethal and potentially curative in mice with aggressive DLBCL co-overexpressing MYC and BCL2.

Pub. Date : 2014

PMID : 24893165






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Together, our data suggest that the interaction between alisertib plus VCR plus rituximab is synergistic and synthetic lethal in Myc and Bcl-2 co-expressing DLBCL. MLN 8237 BCL2 apoptosis regulator Homo sapiens